Targeting herpesvirus reliance of the chemokine system.
Viral infections depend on an intimate relationship between the infectious agent and the host cells. Viruses need the host cells for replication, while the innate- and adaptive- immunesystem of the host is fighting to kill the infected cell in order to clear out the pathogen and survive the infection. However, since both virus and host exist, the organisms struggle must reach an ecological equilibrium. Among the best-studied interactions between viruses and the host immune system are those between herpesviruses and their hosts. Herpesviruses are known to devote a significant part of their large genomes on immuno-modulatory genes, some encoding chemokines or chemokine receptors. These genes, which may be dispensable for viral replication in vitro, are highly important for viral growth in vivo, for viral dissemination and disease progression. Indeed, all beta and gamma-herpesviruses have acquired homologs of both chemokines and chemokine receptors belonging to the 7 transmembrane (7TM) spanning, G protein-coupled receptor family. 7TM receptors are very efficient drug targets and are currently the most popular class of investigational drug targets. A notable trait for the virus encoded chemokine receptors seems to be their constitutive activity. The biological function of the constitutive activity is still unclear, but it has become clear that the receptors are involved in important parts of the viral lifecycle in vivo, and that the receptor signaling is involved in gamma-herpesvirus mediated cell transformation. Therefore, blocking the signaling of these receptors will provide an efficient and highly specific way to inhibit viral replication in vivo and disease progression in the hosts.
Rosenkilde
Mette M
MM
Laboratory for Molecular Pharmacology, Department of Pharmacology, Panum Institute, University of Copenhagen, Copenhagen, Denmark. Rosenkilde@molpharm.dk
Kledal
Thomas N
TN
D000818:Animals; D018925:Chemokines / Q000096:biosynthesis / Q000502:physiology*; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy / Q000503:physiopathology; D006564:Herpesviridae / Q000502:physiology; D006566:Herpesviridae Infections / Q000188:drug therapy* / Q000503:physiopathology* / Q000821:virology; D006801:Humans; D019707:Receptors, Chemokine / Q000096:biosynthesis / Q000502:physiology; D043562:Receptors, G-Protein-Coupled / Q000187:drug effects / Q000502:physiology
D018925:Chemokines; D019707:Receptors, Chemokine; D043562:Receptors, G-Protein-Coupled